Loading…
← CockpitCompetitor Analysis › 7575.T Japan Lifeline Co., Ltd.Open in the cockpit ↗

Japan Lifeline Co., Ltd.7575.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum leader 93
Mkt cap
$703M
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$2.12M
20-day average traded
Fwd P/E
14.5×
forward earnings
ROIC−WACC
+8.6 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥1,713
1D-0.8%
1W+4.0%
1M+9.9%
3M+12.0%
6M+33.7%
YTD+8.7%
1Y+17.1%
ATR %2.3%
52w lowhigh1.2% off high

What Japan Lifeline does

Employees: 1,304

Japan Lifeline at a glance

Size Japan Lifeline (7575.T) is a Japan Health Care company (Medical Specialties) with a market value of $703M, the 911th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,713 on 18 Nov 2026.

Performance Over six months the shares gained 33.7%, against -15.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 5.8% over the last twelve months (peer median +14.8%); the operating margin is 18.7% (peer median 10.6%).

Valuation It trades at 14.5× forward earnings against a peer median of 23.2× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.6 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 20267575.T 135Peer median 86
Six months, rebased to 100: Japan Lifeline against the median of its 20 peers (local-currency closes).

Japan Lifeline financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥61.3B¥59.2B¥56.6B¥51.4B¥51.8B
Revenue growth—+5%+10%-1%—
Gross profit¥35.6B¥34.5B¥33.1B¥30.4B¥29.0B
EBITDA¥13.1B¥14.4B¥14.6B¥12.8B¥12.7B
Net income¥9.01B¥9.35B¥9.32B¥7.51B¥6.89B
Free cash flown/a¥6.27B¥7.56B¥4.79B¥10.7B
Capital expendituren/a¥1.97B¥1.99B¥2.34B¥1.73B
Total debt¥3.58B¥3.12B¥3.97B¥4.63B¥6.88B

Quarterly statements and history in the cockpit →

Japan Lifeline competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%6884101501301234300622688085688389491000301122DCTH002876688179301367600855INMD603108300453300326SNT002950QDEL7575.T6-month return →1-month return →
Up and to the right = strong over both horizons. Japan Lifeline is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×6884101501300622688085688389301122DCTH002876INMD6031083003267575.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Japan Lifeline is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%6884101501301234300622688085DCTH002876INMD603108300326SNT7575.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Japan Lifeline is the large dot.

Japan Lifeline competitors and peer comparison

How Japan Lifeline compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Japan Lifeline against its 20 peers (data as of 18 Nov 2026)
Measure7575.TPeer medianRank in peer set
1-month return+9.9%-8.9%3rd highest of 21
6-month return+33.7%-15.1%4th highest of 21
Distance from 52-week high-1.2%-38.3%highest of 21
Revenue growth (TTM)+5.8%+14.8%7th lowest of 21
Operating margin18.7%10.6%5th highest of 21
Forward P/E14.5×23.2×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)-9.5%10.1%2nd least demanding of 16
Growth delivered (Del g)+2.9%+14.2%4th lowest of 16
Hurdle (Req g minus delivered)-12.4 pp-9.8 pp8th least demanding of 16
ROIC minus cost of capital+8.6 pp+2.3 pp7th highest of 21
EV / EBITDA7.9×11.1×2nd cheapest of 6
Net debt / EBITDA-0.6×-1.7×3rd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a

Questions

Which companies are Japan Lifeline's closest peers?
The cockpit's peer set: SWS Hemodialysis Care (688410.SS), Shanghai INT Medical Instruments (1501.HK), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Doctorglasses Chain (300622.SZ), Shanghai Sanyou Medical (688085.SS), Shenzhen Lifotronic Technology (688389.SS), Livsmed (491000.KS), Caina Technology (301122.SZ).
Is Japan Lifeline expensive compared with its peers?
On forward p/e it trades at 14.5× against a peer median of 23.2×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Japan Lifeline stock performed?
Over six months to 18 Nov 2026 the shares returned +33.7% against -15.1% for the median peer; over one year +17.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.